Obesity battle heats up again as Novo claws its way back into race with Lilly

🇯🇵 The Japan Times (JP) —

AI Summary

Novo Nordisk strengthens its position in the obesity treatment market with its weight-loss drug Wegovy, maintaining a lead over Eli Lilly's newly launched Foundayo. This intensifies competition in pharmaceuticals focused on weight management.

Novo Nordisk is getting a boost from its new Wegovy weight-loss pill that ​is holding onto its lead against Eli Lilly's more recently launched Foundayo.

Markets Health Novo Nordisk obesity weight-loss drug Wegovy Eli Lilly Foundayo pharmaceutical competition

Read original source →